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SUMMARY 
Background: Clinical, genetic and neuroimaging studies indicated strong evidence against traditional diagnostic separation of 
bipolar disorder from schizophrenia. In this study, we aimed to evaluate hypomanic symptoms and influence on general functioning
among psychotic patients.
Subjects and methods: Patients with schizophrenia and other psychotic disorders were assessed between June and September 
2010. Positive and Negative Symptom Scale (PANSS), Hypomania Check List-32 (HCL-32), Mood Disorders Questionnaire (MDQ) 
and General Assessment of Functioning Scale (GAS) were applied to all 93 patients. Answers of self-rating scales were confirmed
with hospital records.  
Results: Mean age was 35.7±9.5 years, mean age of onset was 20.3±5.3 years and duration of illness was 15.4±9.2 years. 30.1% 
of the patients, had a history of mood stabilizer treatment taken at least one month while one five of the patients had different 
psychiatric diagnosis other than current diagnosis. 26.9% of the patients with psychotic disorders had positive scores on both MDQ 
and HCL-32 but there were no significant difference between patients in terms of general functioning (p=0.82).  
Conclusions: As reported in this study, there is no simple, clear-cut between schizophrenia and bipolar affective disorder.  
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*  *  *  *  *  
INTRODUCTION
Emil Kraepelin’s suggestion at the turn of the 20th 
century that manic depression could be differentiated 
from dementia praecox strongly influenced western 
psychiatry within a relatively short period (Altınbaú et 
al. 2011). Although Kraepelin’s fundamental dicho-
tomy has persisted for many years, vigorous debates 
about nosology have often occurred (Altınbaú et al. 
2011, Angst & Gamma 2008, Crow 2008, Fischer & 
Carpenter 2009). Eugen Bleuler (1924) disagreed with 
Kraepelin, conceptualizing the relationship between 
affective illness and schizophrenia as a continuum 
without a sharp line of demarcation. According to 
Bleuler’s view, a patient was either predominantly 
schizophrenic or predominantly manic-depressive with 
most patients situated somewhere along this spectrum 
(Goodwin & Jamison 2007). Eventually, the view that 
bipolar disorder and schizophrenia are mainly distinct 
diagnostic entities has been widely accepted in recent 
decades as reflected in the current classifications 
systems, the American Psychiatric Association’s Dia-
gnostic and Statistical Manual, fifth revision (DSM-5) 
and the World Health Organization’s International 
Classification of Diseases, tenth edition (ICD-10). This 
is despite the reality that many individuals with severe 
psychiatric illness have both prominent mood and 
psychotic symptoms – raising the possibility, and 
indeed the likelihood, that there is no simple, clear-cut 
biological (and diagnostic) distinction between 
schizophrenia and bipolar disorder. 
Family studies, twin studies, genome-wide linkage 
studies and association studies fail to support the 
traditional diagnostic separation of bipolar disorder 
from schizophrenia (Craddock et al. 2005). Whereas it 
was originally thought that schizophrenia was an 
illness of delusions and hallucinations, Crow was the 
first to suggest the existence of more than one 
“syndrome” of schizophrenia, that may involve more 
than one disease process (Crow 1980). Recent studies 
using complex statistical methods indicate that 
schizophrenia includes different syndromes, including 
positive symptoms, negative symptoms, disorganiza-
tion, mania and depression (Dikeos et al. 2006, Boks et 
al. 2007, Egli et al. 2009). It is now well established 
that mood symptoms (both depressive and manic) are 
relatively common in patients with schizophrenia. 
Furthermore, depressive symptoms have been shown 
to have significant prognostic implications for patients 
with schizophrenia, with depressive symptoms in the 
acute psychotic phase of the illness an indicator of 
better prognosis, but post-psychotic depression an 
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indicator of poorer prognosis (Oosthuizen et al. 2008). 
Based on such findings, we aim to evaluate 
(hypo)manic symptoms in schizophrenia and other 
psychotic disorders and their impact on functioning. 
SUBJECTS AND METHODS 
Participants and study protocol 
Schizophrenic and other psychotic patients attending 
to outpatient clinics were assessed for recruitment 
process according to inclusion and exclusion criteria. 
Patients between the ages 18-65 years and diagnosed 
with Schizophrenia or other psychotic disorders (delu-
sional disorder, schizoaffective disorder, Psychosis Not 
Otherwise Specified (NOS)) were recruited for the 
study. Exclusion criteria were diagnosis of brief 
psychosis, schizophreniform disorder, history of alcohol 
and drug use disorder, Positive and Negative Symptom 
Scale (PANNS) scores >50 and hospitalization in the 
last 2 months. All patients signed written informed 
consents for participating to the study and local ethic 
committee approval was taken. 
Data collection 
Patients were assessed consecutively between 1st
June-1st September. Ninety three patients were inclu-
ded for the study according to inclusion and exclusion 
criteria as defined above. The PANSS, Hypomania 
Check List-32 (HCL-32), Mood Disorders Ques-
tionnaire (MDQ) and General Assessment of Func-
tioning Scale (GAS) were applied to all patients by 
two experienced clinicians (S.Y. and H.I.A.) and 
clinical diagnoses were confirmed with Structured 
Clinical Interview for DSM Disorders-I.  
MDQ and HCL-32 both are self-report instruments 
which screen lifetime history of manic and/or hypo-
manic symptoms. MDQ includes 13 yes/no questions 
mainly derived from DSM-IV in the first sub-item and 
second sub-item asks whether several of any reported 
manic or hypomanic symptoms or behaviors were 
experienced during the same period of time. Lastly, the 
level of functional impairment related with these 
manic and/or hypomanic symptoms are asked with a 4-
point scale (Hirschfeld et al. 2000).Other mood 
questionnaire, HCL-32 assesses symptoms in greater 
detail than DSM IV based structured clinical interview 
with 32 questions screening manic and/or hypomanic 
symptoms including active-elevated and irritable-risk 
taking sub-scales (Angst et al. 2005). The optimal cut-
off points have been reported to be a score of 7 or 
higher for MDQ and 14 or higher for HCL-32.GAS is 
a rating scale developed for evaluating the overall 
functioning of an individual for a specified time period 
on a continuum from severe psychiatric symptoms to 
health (Endicott et al. 1976). 
Socio-demographic and clinical variables of patients 
were completed during interviews with the patients and 
confirmed using hospital records. “Positive scores” that 
shows high probability of a mood disorder considered as 
higher scores on the cut of point (14) of the HCL-32 
and MDQ ( 7 positive answers on the first item and 
yes answer for the second item). 
Statistical Analysis 
Statistical analysis was performed with the 
Statistical Package for Social Sciences (SPSS) 13 for 
Windows. Descriptive statistics were used for defining 
socio-demographic and basic clinical variables (e.g. 
illness onset, duration of illness). The chi-square test 
was used to compare the nominal and ordinal demo-
graphic variables. The Mann-Whitney U test was used 
for comparing GAS scores of the patients with and 
without positive mood scores on the MDQ and HCL-32 
scales. Differences were considered significant at 
p<0.05 for all tests.  
RESULTS 
Most of the patients were male (n=70, 75.3%), not 
married (n=78, 83.9%) and only 21.5% of patients 
(n=20) were currently in employment. Diagnosis of the 
patients were schizophrenia (n=80, 86%), psychosis 
NOS (n=11, 11.8%), schizoaffective disorder (n=1, 
1.1%) and delusional disorder (n=1, 1.1%). The mean 
age of patients was 35.7±9.5 years, mean age of onset 
was 20.3±5.3 years and duration of illness was 15.4±9.2 
years. Approximately one third of the patients (n=28, 
30.1%) had a history of mood stabilizer treatment taken 
for at least one month (Valproate n=20, Carbamazepine 
n=4, Lithium n=3, Lithium + Valproate n=1). Family 
history of psychiatric disorders among first degree 
relatives of patients was 37.7% (Psychotic disorders: 
16.1%, depression: 15.1%, hospitalized but diagnosis 
could not be clarified: 3.2%, taking treatment but 
diagnosis could not be clarified: 2.2%, anxiety disorder: 
1.1%). 
The proportion of patients who scored 7 to the first 
item and answered yes to the second item of the MDQ 
was 29.0% (n=27). Also, 36.6% (n=34) of patients 
experienced 14 hypomanic symptoms on the HCL-32. 
The proportion of the patients who had positive scores 
on both the MDQ (7 or higher scores on the first item 
and yes answer for the second item) and HCL-32 (14 or 
higher scores) were 26.9% (n=25) that shows high 
probability of a mood disorder.  
The mean scores of MDQ, HCL-32, PANSS and 
GAS are summarized in Table 1. There was no 
statistically significant difference between patients with 
and without positive mood scores in terms of age 
(p=0.66), duration of illness (p=0.72), total PANSS 
(p=0.96) and GAS scores (p=0.82) (Table 2). 
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Table 1. Descriptive values of the Symptom Scales 
Scale Min. Max. Mean Median SD 
PANSS-P     7.0     9.0   8.7   8.0   2.4 
PANSS-N     7.0   42.0 10.7   8.0   5.3 
PANSS-G  16.0   40.0 18.7 16.0   4.5 
MDQ(item 1)  0   14.0   4.1   3.0   4.3 
HCL-32(item 3)  0   28.0   8.1 13.0   9.8 
GAS 30 90 48.2 40.0 13.7 
HCL-32: Hypomania Checklist-32, MDQ: Mood Disorders Questionnaire, PANSS: Positive and Negative Symptom Scale 
GAS: General Assessment of Functioning Scale 
Table 2. Comparison of General Functioning
Positive mood scores Mean GAS score Z p* 
Yes 45.5 -0.23 0.82 
No 46.9 -0.23 0.82 
*Compared with Man-Whitney-U test, p>0.05 non-significant 
DISCUSSION 
In recent years, emerging evidence from clinical, 
neuroimaging and genetic studies suggests that the 
division between both unipolar depression and bipolar 
disorder and between bipolar disorder and schizophrenia 
is likely to be over-lapping (Craddock et al. 2005, Crow 
1980, Dikeos et al. 2006, Boks et al. 2007, Egli et al. 
2009, Lichtenstein et al. 2009, Craddock & Sklar 2013). 
A dimensional classification of mood and psychotic 
disorders has been proposed by several authors in the 
light of the evidence that genetic factors for schizo-
phrenia and the mood disorders overlap (Craddock et al. 
2004, Angst 2007, Malhi et al. 2008, Abrams et al. 
2008, Henry & Etain 2010, Juli et al. 2012, Potuzak et 
al. 2012.). The DISC1 (Disrupted in Schizophrenia 1) 
and NG1 (Neuregulin-1) genes can be considered good 
examples of overlap as these genes are found to be 
associated with mixed features of schizophrenia and 
mania, or unitary psychosis (Green et al. 2005, 
Hodgkinson et al. 2004). In line with the genetic evi-
dence, neuroimaging studies indicate that bipolar 
disorders and schizophrenia share similar brain regions 
such as the prefrontal cortex, thalamus, left caudate, left 
medial temporal lobe, and right insula (Yu et al. 2010). 
On the other hand, clinical data analyses with 
advanced statistical methods such as cluster analyses 
and factor analyses suggest that schizophrenia consists 
of many different syndromes. These syndrome clusters 
are mainly include positive symptoms, negative 
symptoms, mania, depression and disorganizations. 
These syndromes are not unique to schizophrenia only 
as existed in mood disorders (Ratakonda et al. 1998, 
Murray et al. 2005, Allardyce et al. 2007, Lage et al. 
2011). In line with these findings, we found that 26.9% 
of the patients with schizophrenia or psychotic disorder 
have had both prominent mood and psychotic symptoms 
which supports the dimensional model. Consistently, 
one fifth of the patients had different psychiatric 
diagnoses other than their current diagnosis during their 
illness course and 15.1% of their first degree relatives 
had history of depression that may indicate genetic 
heterogeneity of psychotic disorders. Moreover, Boks et 
al. (2007) reported different clusters of symptoms in 
patients with schizophrenia, including depressive and 
manic symptoms providing an evidence for spectrum 
model. Furthermore, Häfner and colleagues (2008) 
evaluated the data of 107 patients with schizophrenia 
and found that 18% of the patients experienced 
nonpsychotic depressive episodes over a mean follow-
up of 134 months (11.2 years). They also reported that 
patients with schizophrenia experienced manic symp-
toms for up to 5.8 months and that the prevalence of 
manic symptoms per month was up to 40% (over 134 
months of follow-up). Overall, depression remained the 
most frequent syndrome during the course of schizo-
phrenia. Similarly, Bressan et al. (2003) conducted a 
one-year follow-up study of first episode schizophrenia 
and found that 16.3% of the psychotic episodes fulfilled
the DSM-IV criteria for a major depressive episode. 
Although the prevalence of depressive symptoms and 
episodes studied varied widely, data on the hypomanic/ 
manic symptoms in schizophrenia is still limited. The 
reason might be related with the diagnosis of schizo-
affective disorder which may reflect the co-occurrence 
of mood and psychotic disorders. 
Recently, there is still a debate on the diagnostic 
stability and reliability of schizoaffective disorder even 
it remains in DSM-5 (APA 2013). The relative lack of 
stability and reliability of diagnoses influences other 
aspects of schizoaffective disorder, including func-
tioning.Although there are studies suggesting that the 
long-term functioning of persons with schizoaffective 
disorder is similar to schizophrenia (Dissanayake et al. 
2011, Kotov et al. 2013), there is a consensus that 
patients with schizoaffective disorder have better 
functioning than patients with schizophrenia but worse 
than those with mood disorders (Ratakonda et al. 1998, 
Bressan et al. 2003, Hodgkinson et al. 2004, Green et al. 
2005, Murray et al. 2005, Allardyce et al. 2007, Angst 
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2007, Abrams et al. 2008, Hafner et al. 2008, Henry & 
Etain 2010, Yu et al. 2010, Lage et al. 2011, Kantrowitz 
& Citrome 2011). From here, it could be concluded that 
existence of mood symptoms might be related with 
better functioning in psychotic disorders even we could 
not find any difference between psychotic patients with 
and without positive mood scores.However, GAS is 
mainly a rating scale for evaluating the overall functio-
ning and this may cause a type 2 error.  
Our study has several limitations. First, we used 
self-rating scales for evaluating hypomanic/manic 
symptoms, even though patients were clinically 
remitted. Exclusion of relatively severe psychotic 
patients might cause a selection bias considering the 
negative correlation between affective and psychotic 
symptoms. Second, GAS is not a sensitive scale for 
detecting the influence of mood symptoms on 
functioning - it is widely used in clinical practice but 
not commonly used in research studies. Third, it would 
be preferable to conduct a prospective study for 
detecting the relationship between lifetime hypomanic 
symptoms and current functioning, instead of a cross-
sectional design as we did. Fourth, our sample was 
relatively small and heterogenous. Lastly, we did not 
take into account the third item (functionality) of 
MDQ which may produce higher percentage of 
positive mood scores than they it was even it was 
confirmed with HCL-32. 
Despite these limitations, our results are important 
for indicating evidence for the validity of a dimensional 
classification of psychiatric disorders. To the best of our 
knowledge, this may be the first study which 
specifically assesses the influence of life-time hypo-
manic/manic symptoms on general functioning among 
psychotic patients.  
CONCLUSIONS 
The DSM and ICD classifications have been very 
helpful for research and clinical practice but it may be 
appropriate to consider a return to a broader view of 
psychiatric disorders. The distinction between schizo-
phrenia and bipolar disorder may not be as clear as the 
current classification system implies. Thus we suggest 
that a spectrum or continuum concept may provide a 
useful way to integrate a variety of observations 
concerning both mood and psychotic disorders. 
However, we did not find any difference in terms of 
functioning measured by GAS, it can also be concluded 
that our findings data do not provide evidence that 
dimensions would be helpful clinically. Besides, 
prospective studies evaluating different aspects of 
functioning specifically would lead a better model for 
dimensional view. Dimensional approaches may also 
allow clinicians to more fully characterize individual 
patients with a long-term view to developing much 
more rational psychological and pharmacological 
interventions. 
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